Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL)

NCT05043571 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05043571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05043571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1
Overall status
Recruiting
Start date
September 8, 2021
Completion date
November 1, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car, car t-cell-related encephalopathy syndrome, lymphoblastic leukemia, lymphoblastic leukemia in children, lymphoblastic leukemia, acute adult, lymphoblastic leukemia, acute, childhood, refractory leukemia